ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

NCABP “Anyone With Same Facts Would Have Come To Same Conclusion

October 28, 1994

NCI Begins Latin American Cancer Research Network

April 10, 2009

Organ Site Review Committee Recommends Continuing Program Despite Some Weak Areas, Suggests Changes

February 5, 1982

Early, Short Course Of Hormonal Therapy May Allow Patients To Live Longer

January 25, 2008

AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III

December 31, 2010

Five Contracts Funded Under Unconventional Innovations Program

October 22, 1999